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Abstract
Three large studies published in recent issues of Breast Cancer
Research reported no overall evidence of an association between
the  CYP17  5′-untranslated region MspA1 polymorphism and
breast cancer. The present commentary briefly highlights a few
important observations and discusses some additional approaches
to further assessment of associations between CYP17 common
variants and breast cancer risk. In particular, the evolution of
evidence on breast cancer and the CYP17 MspA1 variant
suggests that determination of possible interactions between gene
variants postulated to influence risk and nongenetic risk factors
would be more efficiently accomplished by pooled analyses, ideally
involving all studies of breast cancer, than by attempting to
synthesize published information. Furthermore, such analyses
would also be relevant to investigation of potential gene–gene
interactions between CYP17 and other common variants in genes
encoding enzymes that are involved in the synthesis and
inactivation of sex steroid hormones, preferably using optimal sets
of single nucleotide polymorphisms.
Introduction
The importance of hormonal factors in the aetiology of breast
cancer and its response to treatment are firmly established,
and so it would be expected that factors that modulate
hormonal exposure will modify risk. However, in three recent
large studies of breast cancer [1-3] there was no overall
evidence of association with the CYP17  5′-untranslated
region MspA1 polymorphism, which is in contrast to some
earlier work. This polymorphism has been of interest to breast
cancer investigators because the enzyme encoded by the
gene, namely cytochrome P450c17, functions at key branch
points in steroid hormone biosynthesis. Human P450c17
predominantly catalyzes the formation of the precursor
dehydroepiandrosterone (DHEA), which is converted into
androgens and/or oestrogens in the ovary and in peripheral
intracrine tissues (e.g. breast, bone, skin and adipose tissue)
through tissue-specific enzymatic pathways [4-6]. Current
evidence does not support the involvement of this
polymorphism in CYP17 transcriptional regulation [7-9].
Whereas the CYP17 MspA1 genotype has been found to be
associated with circulating oestrogen levels in premeno-
pausal women in some studies [10], in recent large
population-based studies [11] no association with oestradiol
concentrations in either premenopausal or postmenopausal
women was observed, and in postmenopausal women there
were no clear associations with circulating levels of
oestrogens or androgens [12,13]. However, because of the
limitations of functional assays, there is a strong argument
that the primary emphasis should be on epidemiological
evidence for its association with breast cancer risk [14].
CYP17 genotype and breast cancer risk
The effects of genetic factors in aetiology might be expected
to become stronger with earlier age at onset. The results of
previous studies of the association between the MspA1
variant and breast cancer with earlier age of onset were
inconsistent [7,15-26]. This may in part be due to differences
in study methods. For example, some studies were not
population based [16,18,19,22,26], which renders them
susceptible to the effects of selection bias. In one [17] a
substantial proportion of cases was prevalent, which would
bias the results if CYP17 genotype influenced survival. The
studies differed markedly in size, and so they varied in
statistical power to detect an effect.
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The three most recent studies [1-3] were population based,
and only cases with newly incident disease were included.
One included women clearly defined as premenopausal
(aged 50 years and under who still had menstrual cycles or
who reported natural amenorrhoea for less than 6 months
before diagnosis/interview) resident in two regions of
southern Germany [1]. Data on 527 cases with in situ or
invasive disease diagnosed during the period 1992–1995
were compared with data on 904 control individuals
randomly selected from population registers and matched
with cases in terms of age and study region. These represent
about 80% of individuals on whom interview data had been
obtained, and the losses represent the strict application of
criteria for selecting women who were premenopausal and
genotyping failure. There were no differences between the
cases and controls for whom genotype data were available
and the total cases and controls interviewed in terms of the
distribution of sociodemographic factors or putative risk
factors for breast cancer.
Compared with homozygotes for the A1 allele, the age-
adjusted odds ratio (OR) for breast cancer in heterozygotes
was 1.02 (95% confidence interval [CI] 0.80–1.31) and the
OR in homozygotes for the A2 allele was 1.18 (95% CI
0.87–1.61) [1]. These estimates were little changed with
further adjustment for breast cancer risk factors. Possible
effect modification was examined for age at menarche, oral
contraceptive use, parity, age at first full-term pregnancy, and
breastfeeding status. Such a modification was apparent only
for parity, with increased risk among nulliparous women
homozygous for the A2 allele.
The second study [2] included women aged under 60 years
diagnosed in Melbourne or Sydney (Australia) during the
period 1992–1999, with stratified sampling of cases so that
half were diagnosed at age under 40 years. A total of 2303
(1208 under 40 years old; 1095 aged 40–59 years) cases
with invasive breast cancer were identified from cancer
registries [27]. Interviews were completed for 1578 (69%).
After excluding women who were not white, cases aged
under 40 years in whom BRCA1 and BRCA2 mutations were
found (n = 41), and genotyping failures, 1284 cases were
included in the analysis [2]. A total of 1531 controls were
selected from electoral rolls by proportional random sampling,
based on the expected age distribution of cases, of whom
1021 (67%) were interviewed [27]; 679 were included in the
analysis. There is overlap with an earlier report [15] on 369
cases diagnosed under 40 years during the period
1992–1995 and 284 controls. The analysis was stratified by
menopausal status.
In premenopausal women (1043 cases, 529 controls),
compared with A1 homozygotes, the OR for breast cancer in
heterozygotes was 0.88 (95% CI 0.70–1.11) and in A2
homozygotes the OR was 1.09 (95% CI 0.79-1.51) [2]. As in
the German study [1], adjustment for putative risk factors had
little effect on these estimates. Thus, the increased risk in A2
homozygotes that was apparent in women aged under
40 years in a report on a subset of these data [15] was no
longer detectable. In postmenopausal women (241 cases,
150 controls), the OR for heterozygotes was 1.09 (95% CI
0.70–1.70) and for A2 homozygotes the OR was 1.23 (95%
CI 0.66–2.31). In view of the finding in the earlier study that
the increased risk for A2 homozygotes appeared to be
confined to women with a family history of breast cancer in a
first-degree or second-degree relative [15], the overall
analysis was stratified by family history, defined as breast
cancer in a first-degree relative [2]. Among women with such
a family history, the OR associated with homozygosity for the
A2 genotype was 2.5; this was not a statistically significant
finding. For other possible effect modifications, the authors
defined risk categories as in the study conducted by
Ambrosone and coworkers [20], which they considered to be
the most comprehensive previous assessment of effect
modification. Possible effect modification was examined for
age at menarche, oral contraceptive use, age at first birth, use
of hormone replacement therapy and age at menopause. No
evidence of effect modification was found for premenopausal
breast cancer. For postmenopausal women there was a
suggestion that the increased risk for breast cancer
associated with later age at menopause was confined to
women homozygous for the A1 allele.
The third study [3] was restricted to postmenopausal women
resident in Sweden in the period 1993–1995. Long-term
users of menopausal hormones and women with diabetes
mellitus were over-sampled. Comparison was made between
1544 cases of invasive breast cancer (73% of potentially
eligible cases) identified through cancer registers, and 1502
controls (61% of those potentially eligible) selected from the
Swedish Total Population Registry. Compared with A1
homozygotes, the OR for breast cancer in A2 homozygotes
was 1.0 (95% CI 0.8–1.3) and that for heterozygotes was
also unity. This lack of association is consistent with most
previous studies in which results specific to postmenopausal
women were presented [21-26,28], although in studies in
Indian [27] and Japanese [19] women the A2A2 genotype
was associated with increased risk. This lack of association
was also observed when ductal and lobular tumours were
analyzed separately. Possible effect modification was
examined for menopausal hormone use, age at menarche,
age at menopause, age at first birth, parity, and body mass
index. Effect modification was apparent only for age at
menarche, with A2 homozygotes having an increased risk
associated with an early age at menarche and age at
menopause, and with A2 carriers having a reduced risk
associated with an early age at menopause. Unlike in other
studies [29], age at menarche was not associated with
overall breast cancer risk in this study.
In all three studies [1-3] there was more than 80% power to
detect an OR of 1.5 or more at the 0.05 level of statistical240
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significance. As noted in the Australian study [2], detection of
departure from multiplicative joint effects requires at least four
times the number of subjects than would a study aimed only
at detecting the main effects of genotype and another risk
factor [30]. Therefore, the lack of consistency between the
findings of the Australian study [2] and the much smaller
study (96 premenopausal cases and 86 controls; 111
postmenopausal cases and 102 controls) conducted by
Ambrosone and coworkers [20] may reflect the play of
chance. There is consistency between the German [1] and
Australian [2] studies of premenopausal women in the lack of
evidence of a differential effect of CYP17 genotype on risk
associated with age at menarche, age at first birth, or use of
oral contraceptives. The Swedish study [3] of postmeno-
pausal women detected an interaction with age at menarche,
which was interpreted as a chance finding. In contrast to the
German study [1], neither the Swedish [3] nor Australian [2]
studies showed an increased risk associated with presence
of the A2 allele in nulliparous premenopausal women (OR
based on crude analysis of data presented in Table 3 in
reference [2], assuming all parous women had age at first
birth recorded, heterozygotes and A2 homozygotes
combined: 0.94, 95% CI 0.61–1.46). Crude analysis of the
German data [1] suggests that homozygosity for the A2
variant is inversely associated (OR 0.32, 95% CI 0.10–1.04)
with risk for premenopausal breast cancer in women with a
family history of the disease in first-degree relatives, which is
in contrast to the Australian study [2].
In the German [1] and Swedish [3] studies there was no
association between CYP17 genotype and stage of breast
cancer. This is compatible with most [7,17,21,25,31-33] but
not all [16,24,34] previous studies, in which a variety of
definitions of extent of disease were used.
One previous study [23] suggested that a high intake of
lignans – plant compounds that are metabolized in the gut to
produce the phyto-oestrogens enterolactone and enterodiol –
is associated with a more marked reduction in OR for breast
cancer in women who have an A2 allele than in A1
homozygotes. A concern is that this joint effect has been
investigated in other studies but not reported. It is noteworthy
that associations between intake of lignans and breast
cancer was reported in a subset of participants in the
German study [35].
Conclusion
In the analyses of breast cancer in younger women, possible
interactions between CYP17 genotype and other gene
variants affecting the tissue-specific synthesis and
metabolism of steroid hormones do not appear to have been
investigated. The metabolism of any exposure is likely to
depend on the balance between the relative activities of all of
the enzymes in the metabolic pathway [36]. This concept is
of particular importance bearing in mind the role played by
P450c17 in the synthesis of DHEA, a precursor of active
androgens as well as oestrogens, which exert opposite
effects in breast cancer development [5]. In some studies of
breast cancer in general (i.e. not specifically in pre-
menopausal women), suggestions of an interaction with the
17β-hydroxysteroid dehydrogenase type 1 [28,37] and with
CYP1A1  and catechol-O-methyltransferase [26] variants
were observed. Pooled analyses would facilitate the
investigation of gene–gene interactions.
It should also be kept in mind that the determination of the
impact of genetic variant(s) on tissue-specific intracellular sex
steroid concentrations has inherent limitations, because
these levels do not correlate with measurements of
circulating sex steroid levels. Indeed, the serum testosterone
and oestradiol levels reflect predominantly the contribution of
direct sex steroid secretion by the ovaries and/or adrenals
[5]. A better approach to estimating DHEA conversion into
active androgens and oestrogens would be to measure
circulating conjugated metabolites, such as glucuronidated
metabolites [38].
There has been considerable concern about the potential
impact of publication bias on the body of knowledge on
gene–disease associations [39-41]. The potential for
selective publication of results can only increase as a result of
the application of a combination of a tremendous expansion
in genotyping potential and exploratory statistical analyses in
studies with limited sample sizes [42-44]. This problem is
compounded for gene–environment and gene–gene inter-
actions because, in addition to the larger number of potential
comparisons implicit in the concept of multiple interacting
variables, authors face the problem that large tables of gene–
environment interaction estimates are very cumbersome and
difficult to assemble in publishable format [45]. This inevitably
increases the potential for publication bias.
Therefore, the publication of the null overall findings on
CYP17 5′-untranslated region MspA1 genotype and breast
cancer, and of the effect modifications investigated [1,2] is
particularly welcome. Is there a need for further studies of this
polymorphism and breast cancer? The accrued evidence
does not indicate any substantial overall effect in white
populations, but it is insufficient to exclude an effect in other
populations. For the latter, integration of evidence across
studies will most efficiently be accomplished using
systematic review and pooled analysis methods, such as
have been applied in human genome epidemiology reviews
[46]. Possible interaction with family history and with
nongenetic risk factors has been observed in some studies
but has not been replicated. Review of the studies on CYP17
illustrates the difficulties of synthesizing evidence on such
interactions, notably differences in definition and
categorization of variables and in methods of analysis. Pooled
analysis, sometimes described as meta-analysis of individual
patient data, offers many advantages over the meta-analysis
of the results of studies, including consistent determination of241
subgroup effects, standardization of definitions of cases and
variables, and better control of confounding [47,48]. This
approach will be facilitated by the development of networks
of investigators researching gene–disease associations [49].
Is there a need for further studies of genetic variation in
CYP17 and breast cancer? In single studies, no association
has been reported with a G–A transition in the promoter
region in Japan [19] or with the c198t or g255t single
nucleotide polymorphisms (SNPs) in England [13]. The two
SNPs in the latter study, together with the MspA1 variant
(t34c), tag the three common haplotypes in the coding region
[50]. Although the haplotype tagging SNP approach may
prove a valuable direction for gene disease–association
studies, there is considerable debate about the optimal
strategies for selecting SNPs [51-53]. In theory, additional
genotyping of samples from studies already completed would
be an efficient way to confirm the presence or absence of
effect, with synthesis of the evidence across studies.
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